Did New MS Data Just Shift TG Therapeutics' (TGTX) Investment Narrative?

• TG Therapeutics reported that at the October 2026 ACTRIMS-ECTRIMS meeting in Toronto, it presented initial Phase 1 data for its allogeneic CD19-directed CAR T therapy azer-cel in progressive multiple sclerosis alongside a wide set of longer term and real world results for BRIUMVI.
• The breadth of BRIUMVI updates, from seven year outcomes to real world and dosing regimen analyses, highlights how TG Therapeutics is working to deepen evidence around an existing commercial asset while exploring azer-cel as a potential future pillar in multiple sclerosis.
• Attention now shifts to how TG Therapeutics' expanding CAR T and BRIUMVI data package could influence the investment narrative built around its MS franchise.

Spot potential peers to TG Therapeutics in multiple sclerosis and autoimmune therapy by scanning our handpicked 32 healthcare AI stocks, which are pushing the next wave of data driven drug development.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to believe BRIUMVI can keep supporting a high margin MS and autoimmune franchise while the firm absorbs heavy spend on subcutaneous formulations, new indications and now CAR T infrastructure. The ACTRIMS ECTRIMS data focuses that view on execution. It sharpens the conversation around how efficiently management converts an expanding data set into prescriptions and, eventually, durable cash generation.

In the near term, the key swing factor is still progress toward subcutaneous BRIUMVI and a simpler IV initiation label. The Toronto updates look more like incremental support than a major new catalyst. The largest risk does not change. Cost inflation and manufacturing investments could keep squeezing net margins if revenue growth or label changes do not offset the higher expense base.

The late breaking oral presentation on azer cel in progressive multiple sclerosis is the most interesting new angle. It introduces a potential second pillar alongside BRIUMVI, this time in a segment where treatment options are more limited. For an investor, the relevance is less about immediate revenue and more about whether TG Therapeutics can credibly extend its B cell expertise into cell therapy without overwhelming the P&L.

If azer cel’s initial Phase 1 readout is encouraging on safety and biological activity, it becomes part of the medium term catalyst stack, alongside subcutaneous BRIUMVI and label simplification from ENHANCE. If the data are underwhelming or show safety complexity, the risk is incremental spend on a capital intensive platform that competes with BRIUMVI manufacturing priorities rather than supporting them.

TG Therapeutics' current analyst narrative points to forecast revenue of US$1.8b and expected earnings of US$619.2 million by 2029. These figures are built on an assumed 30.2% yearly revenue growth rate and an earnings increase of about US$177.7 million from US$441.5 million today.

Uncover why TG Therapeutics' fair value indicates a 31% potential upside to its current price before the market closes that gap.

Exploring Other Perspectives

One alternate angle puts azer cel at the center. The most optimistic analysts already modeled TG Therapeutics reaching about US$2.2b in revenue and US$761.4 million in earnings by 2029 before this MS Toronto news. You can treat those richer targets as a ceiling that might shift again once the new data are reflected.

Explore 4 other TG Therapeutics fair value estimates, including one that suggests potential upside of as much as 226% from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your TG Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for TG Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Looking For More Investment Ideas Beyond TG Therapeutics?

If the TG Therapeutics story has sharpened your focus on where risk and reward can line up, it can help to compare it with a broader watchlist. The Simply Wall St Screener lets you filter for the types of businesses that fit your own tolerance for volatility, balance sheet strength and income needs rather than relying on a single MS focused thesis.

• If you want potential mispricing paired with quality fundamentals, scan a curated set of 27 high quality undervalued stocks that might deserve a closer look.
• For steadier profiles where financial resilience matters most, filter for a 31 resilient stocks with low risk scores and see which companies score well on durability.
• When you are hunting for less crowded ideas with solid numbers behind them, work through a 20 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com